Clinical pharmacology of inflammatory bowel disease therapies
- 90 Downloads
Knowledge about the clinical pharmacology of medical therapy of inflammatory bowel disease has incrementally advanced. Small studies with mesalamine have suggested that intestinal mucosal concentrations of mesalamine may predict clinical response to mesalamine therapy. Increased expression of glucocorticoid receptor β and increased expression of the multidrug resistance drug pump P-glycoprotein 170 have been proposed as markers of drug resistance to glucocorticoids. A baseline determination of thiopurine methyltransferase phenotype or genotype may predict early leukopenia in patients treated with azathioprine or 6-mercaptopurine. Serial measurement of erythrocyte 6-thioguanine nucleotides may be useful in tailoring the dose of these medications. A loading dose of intravenous azathioprine does not accelerate the time to response in patients with steroid-treated Crohn's disease; however, standard azathioprine may work more quickly than previously reported. Methotrexate, 15 to 25 mg/wk, is effective for the treatment of Crohn's disease (active or in remission), and there is no significant difference in the erythrocyte concentrations of methotrexate polyglutamate in patients with inflammatory bowel disease receiving 15 mg, compared with 25 mg, subcutaneously on a weekly basis.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Palumbo G, Carlucci G, Mazzeo P, et al.: Simultaneous determination of 5-aminosalicylic acid, acetyl-5-aminosalicylic acid and 2,5-dihydroxybenzoic acid in endoscopic intestinal biopsy samples in humans by high-performance liquid chromatography with electrochemical detection. J Pharmacol Biomed Anal 1995, 14:175–180.CrossRefGoogle Scholar
- 19.Bourgeois S, Gruol DJ, Newby RF, Rajah FM: Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 1993, 7:840–851. Initial report indicating that increased glucocorticoid receptor b concentrations are associated with steroid resistance in patients with ulcerative colitis.PubMedCrossRefGoogle Scholar
- 21.Schottelius A, Wedel S, Weltrich R, et al.: Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol 2000, 95:1994–1999. Initial report indicating that increased multidrug resistence-1 gene product, P-glycoprotein 170, is associated with steroid resistance in patients with ulcerative colitis.PubMedCrossRefGoogle Scholar
- 26.Yates CR, Krynetski EY, Loennechen T, et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance [see comments]. Ann Intern Med 1997, 126:608–614. Initial report that early leukopenia is associated with low or intermediate thiopurine methyltransferase genotype in patients with Crohn's disease treated with azathioprine.PubMedGoogle Scholar
- 34.Cuffari C, Theoret Y, Latour S, Seidman G: 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401–406. First larger report indicating that measurement of 6-thioguanine in the erythrocytes of patients with inflammatory bowel disease treated with 6-mercaptopurine or azathioprine may help to tailor therapy.PubMedGoogle Scholar
- 35.Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713. Report from a randomized, controlled trial demonstrating no benefit for an intravenous loading dose of azathioprine for accelerating remission in active, steroid-treated Crohn's disease.PubMedCrossRefGoogle Scholar
- 37.Cross-sectional study of IBD patients taking azathioprine (AZA) or 6-mercaptopurine (6MP): lack of correlation between disease activity and 6-thioguanine nucleotide (6TGN) concentration [abstract]. Gastroenterology 2000, 118:A788.Google Scholar
- 45.Moshkowitz M, Oren R, Tishler M, et al.: The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997, 11:569–573. Report from a pharmacokinetic study demonstrating that subcutaneously administered methotrexate, 15 to 25 mg/wk, achieves pharmacologically active concentrations in the gut lumen and mucosa at the 1-week trough time point.PubMedCrossRefGoogle Scholar